

1 **Molecular architecture of nucleosome remodeling and**
2 **deacetylase sub-complexes by integrative structure**
3 **determination**

4
5
6
7
8 Shreyas Arvindkar¹, Matthew J. Jackman², Jason K.K. Low³, Michael J. Landsberg^{2, *}, Joel
9 P. Mackay^{3, *}, and Shruthi Viswanath^{1, *}

10
11 ¹National Center for Biological Sciences, Tata Institute of Fundamental Research, Bangalore,
12 India

13 ²School of Chemistry and Molecular Biosciences, University of Queensland, QLD, Australia

14 ³School of Life and Environmental Sciences, University of Sydney, NSW, Australia

15
16 *Corresponding authors E-mail: m.landsberg@uq.edu.au (M.J.L.);
17 joel.mackay@sydney.edu.au (J.P.M.); shruthiv@ncbs.res.in (S.V.)

18
19
20
21
22
23 Short title: Integrative models of NuRD sub-complexes
24
25
26
27

28 Abstract

29 The Nucleosome Remodeling and Deacetylase (NuRD) complex is a chromatin-modifying
30 assembly that regulates gene expression and DNA damage repair. Despite its importance,
31 limited structural information is available on the complex and a detailed understanding of its
32 mechanism is lacking. We investigated the molecular architecture of three NuRD sub-
33 complexes: MTA1-HDAC1-RBBP4 (MHR), MTA1^N-HDAC1-MBD3^{GATAD2CC} (MHM), and MTA1-
34 HDAC1-RBBP4-MBD3-GATAD2 (NuDe) using Bayesian integrative structure determination
35 with IMP (Integrative Modeling Platform), drawing on information from SEC-MALLS, DIA-MS,
36 XLMS, negative stain EM, X-ray crystallography, NMR spectroscopy, secondary structure and
37 homology predictions. The structures were corroborated by independent cryo-EM maps,
38 biochemical assays, and known cancer-associated mutations. Our integrative structure of the
39 2:2:2 MHM complex shows asymmetric binding of MBD3, whereas our structure of the NuDe
40 complex shows MBD3 localized precisely to a single position distant from the MTA1
41 dimerization interface. Our models suggest a possible mechanism by which asymmetry is
42 introduced in NuRD, and indicate three previously unrecognized subunit interfaces in NuDe:
43 HDAC1^C-MTA1^{BAH}, MTA1^{BAH}-MBD3, and HDAC1⁶⁰⁻¹⁰⁰-MBD3. We observed that a significant
44 number of cancer-associated mutations mapped to protein-protein interfaces in NuDe. Our
45 approach also allows us to localize regions of unknown structure, such as HDAC1^C and
46 MBD3^{IDR}, thereby resulting in the most complete structural characterization of these NuRD sub-
47 complexes so far.
48

49 Introduction

50 The Nucleosome Remodeling and Deacetylase (NuRD) complex is a multi-protein chromatin-
51 modifying assembly, expressed in most metazoan tissues, and conserved across multi-cellular
52 animals (Basta and Rauchman, 2017; Denslow and Wade, 2007; Lejon et al., 2011; Yoshida
53 et al., 2008). It regulates gene expression and DNA damage repair (Basta and Rauchman,
54 2017, 2015; Denslow and Wade, 2007; Li and Kumar, 2010; Reynolds et al., 2013; Smeenk et
55 al., 2010; Yoshida et al., 2008). It modulates nucleosome accessibility in enhancers and
56 promoters for transcription factors and RNA polymerases, thereby regulating the expression of
57 target genes (Bornelöv et al., 2018; Burgold et al., 2019). Subunits of NuRD are implicated in
58 human cancers and various congenital defects (Basta and Rauchman, 2015; Toh and Nicolson,
59 2009). Considerable diversity is observed in subunit isoforms and NuRD-associated factors
60 across tissues (Burgold et al., 2019; Denslow and Wade, 2007; Hoffmann and Spengler, 2019).
61 NuRD comprises two catalytic modules – a histone deacetylase module and ATP-dependent
62 chromatin-remodeling module (Burgold et al., 2019; Denslow and Wade, 2007; Low et al.,
63 2020). The deacetylase module contains metastasis-associated proteins (MTA1/2/3) that form
64 a dimeric scaffold for the histone deacetylases (HDAC1/2). It also contains the chaperones
65 RBBP4/7, which mediate interactions of NuRD with histone tails and transcription factors (Basta
66 and Rauchman, 2017, 2015; Hong et al., 2005). The chromatin-remodeling module contains
67 methyl-CpG DNA binding proteins (MBD2/3) that recruit NuRD to methylated and/or hemi-
68 methylated DNA, GATA-type zinc-finger proteins (GATAD2A/B), and an ATP-dependent DNA
69 translocase (CHD3/4/5) (Burgold et al., 2019; Low et al., 2020).

70
71 Some structural information is available for the complex. Several attempts made to determine
72 the stoichiometry of the endogenous NuRD complex have returned variable results (Bode et
73 al., 2016; Guo et al., 2019; Kloet et al., 2015; Sharifi Tabar et al., 2019; Smits et al., 2013;
74 Spruijt et al., 2016; Zhang et al., 2016). A recent characterization by quantitative mass
75 spectrometry from (Low et al., 2020) reported a 2:2:4:1:1:1

76 (MTA1:HDAC1:RBBP4:MBD3:GATAD2A:CHD4) stoichiometry for the full NuRD complex.
77 Atomic structures of parts of the NuRD complex, including the MTA1-HDAC1 dimer, RBBP4
78 bound to MTA1, the MBD domain of MBD3, and the coiled-coil dimer of MBD2 and GATAD2A
79 have been determined by X-ray crystallography and NMR spectroscopy (Alqarni et al., 2014;
80 Cramer et al., 2014; Gnanapragasam et al., 2011; Millard et al., 2016, 2013). Structures of the
81 2:2 MTA1-HDAC1 dimer, the 2:2:4 MTA1-HDAC1-RBBP4 complex (MHR), the 2:2:2 MTA1^N-
82 HDAC1-MBD3^{GATAD2CC} (MHM) complex, the 2:2:4:1:1 MTA1-HDAC1-RBBP4-MBD3-GATAD2
83 (NuDe complex), and CHD4 bound to a nucleosome substrate have also been characterized
84 at various resolutions by negative stain and/or cryo-electron microscopy (Farnung et al., 2020;
85 Low et al., 2020; Millard et al., 2020, 2016).

86
87 Pairwise interactions between domains and subunits within the MHR, MHM, NuDe, and the
88 endogenous NuRD complexes have also been characterized by chemical crosslinking and
89 mass spectrometry (XLMS) (Low et al., 2020; Millard et al., 2016). A model of the MHM
90 complex, based on crosslinks-driven rigid-body docking of known atomic structures with a pair
91 of MTA1-RBBP4 structures manually placed, has also been reported (Low et al., 2020). While
92 this represents the most complete model of NuRD architecture, it still only accounts for 30% of
93 residues in the NuRD complex. In fact, only 50% of residues in NuRD have known or readily
94 modeled atomic structures, and the structures of proteins such as MBD3, CHD4, and GATAD2
95 are largely uncharacterized. More recent artificial intelligence-based methods such as
96 AlphaFold are also unable to resolve these uncharacterized regions (Jumper et al., 2021).
97 Owing to variability in the paralogue composition as well as significant structural dynamics, the
98 atomic structure of the entire NuRD complex is still undetermined and is likely to remain a
99 challenge for some time to come.

100

101 The 2:2:4 MTA1-HDAC1-RBBP4 complex (MHR) forms the deacetylase core of NuRD. MBD3
102 binds to the N-terminal half of MTA1 to form a 2:2:2 MTA1^N-HDAC1-MBD3^{GATAD2CC} (MHM)
103 complex, which contains two copies of MBD3 (Low et al., 2020). However, the 2:2:4:1:1 MTA1-
104 HDAC1-RBBP4-MBD3-GATAD2 (NuDe complex) and the endogenous NuRD complex are
105 asymmetric, both containing a single copy of MBD3 (Low et al., 2020). The mechanism by
106 which this asymmetry is introduced in NuDe/NuRD is not known. The structure of full-length
107 MBD3 is unknown and it contains a significant intrinsically disordered region (IDR; MBD3⁷¹⁻²¹³),
108 which has been shown to be critical for recruiting the deacetylase core in case of MBD2 (Desai
109 et al., 2015). The localization of full-length MBD3 in NuDe/NuRD is also not known.

110

111 Here, we investigated the molecular architecture of the MHR, MHM, and NuDe complexes
112 using an integrative approach. Integrative structure determination is a method for investigating
113 structures of large assemblies which are refractory to a single experimental method such as X-
114 ray crystallography or cryo-electron microscopy (Alber et al., 2007; Ganesan et al., 2020;
115 Gutierrez et al., 2020; Kim et al., 2018; Rout and Sali, 2019; Russel et al., 2012; Viswanath et
116 al., 2017a; Ward et al., 2013). Using Bayesian integrative modeling with the Integrative
117 Modeling Platform (IMP), we combined data from complementary experiments, physical
118 principles, statistical inference, and prior models. This approach allowed us to combine noisy,
119 sparse, ambiguous, and incoherent data at various resolutions (Alber et al., 2007; Rieping et

120 al., 2005; Rout and Sali, 2019; Schneidman-Duhovny et al., 2014). It produced an ensemble of
121 models consistent with the input information, allowing us to obtain precise uncertainty bounds
122 on the structure (Saltzberg et al., 2019, 2021; Viswanath et al., 2017b; Webb et al., 2018). We
123 used data from SEC-MALLS, DIA-MS, XLMS, negative stain EM, X-ray crystallography, NMR
124 spectroscopy, secondary structure and homology predictions, and stereochemistry
125 considerations (Alqarni et al., 2014; Connelly et al., 2006; Cramer et al., 2014; Gnanaprasam
126 et al., 2011; Low et al., 2020; Millard et al., 2016, 2013). These integrative structures were
127 corroborated by independent cryo-EM maps, biochemical assays, and known cancer-
128 associated mutations, a significant number of which mapped to protein-protein interfaces in the
129 structures (Desai et al., 2015; Forbes et al., 2006; Millard et al., 2020; Pflum et al., 2001; Zhang
130 et al., 1999). By using all available information, the accuracy, precision, completeness, and
131 efficiency of structure determination was maximized (Alber et al., 2007; Rout and Sali, 2019;
132 Russel et al., 2012).

133

134 **Results**




Fig. 1 Integrative structure determination of NuRD sub-complexes Schematic describing the workflow for integrative structure determination of NuRD sub-complexes. The first row describes the input information. The second-row details how data is used to encode spatial restraints. The third row mentions the sampling method and the last two rows illustrate the analysis and validation protocol. The background colors of the input information indicate the stage of modeling in which the information is used, as shown in the legend at the top.

Integrative modeling workflow

The integrative modeling of the MHR, MHM, and NuDe complexes proceeded in four stages (Fig. 1, Material and Methods) (Alber et al., 2007; Rout and Sali, 2019; Russel et al., 2012). The modeled NuRD proteins (subunits), their domains, their representation, and the number of copies in the modeled complexes are shown (Fig. S1A-S1C). The stoichiometry of the modeled proteins was informed by DIA-MS and SEC-MALLS experiments (Fig. S1C) (Low et al., 2020).

135
136
137
138
139
140
141
142
143
144
145
146
147

148 Regarding paralogs, a single representative for each protein was chosen for this work for
149 simplicity, namely MTA1, HDAC1, RBBP4, MBD3 and GATAD2A (Fig. S1A).

150
151 We first represented each protein as a series of beads of size that depends on the degree of
152 knowledge of the structure (and can vary throughout the sequence). Protein domains with
153 known atomic structures (such as the MTA1-HDAC1 dimer) were represented at 1 and 10
154 residues per bead and modeled as rigid bodies, whereas domains without known structure
155 (such as the MBD3^{IDR}) were coarse-grained at 30 residues per bead and modeled as flexible
156 strings of beads (Fig. S1A-S1B). Data from chemical crosslinking combined with mass
157 spectrometry (XL-MS) were used to restrain the distance between cross-linked residues.
158 Negative-stain EM maps were used to restrain the shape of the complexes (Low et al., 2020).

159
160 The simulations started with randomized configurations for the rigid bodies and flexible beads.
161 Over 40 million models per complex were sampled using a Monte Carlo approach (Replica
162 Exchange Gibbs Sampling MCMC; Materials and Methods). The models were scored based
163 on agreement with XL-MS and EM data, together with additional stereochemistry restraints
164 such as connectivity and excluded volume. For each complex, about 20,000 models that
165 sufficiently satisfied the input information were selected for further analysis (Saltzberg et al.,
166 2021).

167
168 These models were clustered based on structural similarity and the precision of the clusters
169 was estimated (Fig. S3-S5) (Saltzberg et al., 2019, 2021; Viswanath et al., 2017b). The quality
170 of the models was assessed by fit to input data (Fig. S6-S8), as well as data not used in
171 modeling, such as independent cryo-EM maps (Millard et al., 2020), published biochemical data
172 (Desai et al., 2015; Millard et al., 2020; Pflum et al., 2001; Zhang et al., 1999) and human
173 cancer-associated mutations (COSMIC) (Table S1) (Forbes et al., 2006). The resulting
174 integrative models were visualized in two ways - a representative bead model and a localization
175 probability density map, and represented in UCSF Chimera and ChimeraX (Pettersen et al.,
176 2021, 2004). The bead model represents the centroid of the major cluster, whereas the
177 localization probability density map represents all models in the major cluster, by specifying the
178 probability of a voxel (3D volume unit) being occupied by a bead in the set of superposed cluster
179 models.

180

181 **MHR**

182 First, to support the integrative modeling of the MHR complex, an *ab initio* 3D EM map for the
183 MHR complex was produced by further analysis of the MHR 2D class averages reported in a
184 previous study (Low et al., 2020). Integrative modeling of the 2:2:4 MHR complex produced
185 effectively a single cluster of models (85% of a total of 15200 models) with a model precision
186 of 27 Å; model precision is the average RMSD between the cluster centroid and models in the
187 cluster (Fig. S3). The models fit very well to the input data as measured by the EM and crosslink
188 scores. 98% of the input crosslinks were satisfied within their uncertainty (Fig. S6). An adipic
189 acid dihydrazide (ADH) / bis(sulfosuccinimidyl)suberate - disuccinimidyl suberate (BS3DSS) /
190 dimethoxy triazinyl methyl-morpholinium chloride (DMTMM) crosslink is violated if the
191 corresponding cross-linked beads are greater than 35 / 35 / 25 Å apart in all models in the
192 cluster. The cross-correlation between the localization probability density map for the models
193 in the major cluster and the input EM map was 0.74, indicating the fit to EM is reasonable but
194 not too high. This could partly be due to unoccupied density in the lobes of the experimental
195 EM map.

196

197 Surprisingly, the representative bead model from the dominant cluster (cluster centroid model)
198 shows the C-terminal half of the two MTA subunits (MTA1⁴³²⁻⁷¹⁵) crossing over (brown and
199 orange MTAs, Fig. 2A, Movie M1). Integrative models of the MHR complex created in the
200 absence of the EM map also showed the MTAs crossing over (Fig. S9).

201
202 The MTA1^{BAH} domain (MTA1¹⁻¹⁶⁴) is positioned distal to the MTA1 dimerization interface
203 (MTA1²⁰⁰⁻²⁹⁰, MTA1^{dimer}), consistent with its position in an independent EM map (Fig. 2B, Fig.
204 2C) (Millard et al., 2020). It is proximal to the HDAC1 active site and may potentially regulate
205 HDAC1 activity (Fig. 2A). This conclusion is consistent with histone deacetylation assays in
206 which MTA1 was shown to modulate HDAC1 deacetylase activity in NuRD (Zhang et al., 1999).
207 Further, for one of the MTAs, the MTA1^{BAH} is located near an RBBP4 (Fig. 2A, Fig. 2B);
208 MTA1^{BAH} proximity to RBBP4 was also indicated in an independent cryo-EM map (Millard et
209 al., 2020). Finally, MTA1^{BAH} is also proximal to the MTA1^{mid} region (MTA1³³⁴⁻⁴³¹) containing the
210 predicted helix (H) and zinc finger regions (ZF) (Fig. 2B, Fig. 2C).

211
212 The MTA1^{mid} region is juxtaposed between MTA1^{dimer} and the MTA1^{BAH} domain (Fig. 2B). In
213 contrast, in a previous crosslink-based MHR model (Low et al., 2020), MTA1^{mid} was proximal
214 to the MTA1^{BAH} domain and distal from the MTA1^{dimer}. The MTA1 C-terminus (MTA1^C; *i.e.*,
215 MTA1⁶⁹²⁻⁷¹⁵) shows considerable conformational heterogeneity and is co-located with MTA1^{USR}
216 (MTA1⁵⁴⁷⁻⁶⁶⁹), the MTA1 disordered region between the R1 and R2 RBBP4 binding regions
217 (Fig. 2B, Movie M1). Overall, many MTA1 domains in the MHR model, such as MTA1^{BAH}
218 domain, MTA1^{mid}, and MTA1^C, are exposed and could possibly interact with nucleosomal DNA
219 and/or other proteins.

220
221 The HDAC1 C-terminus (HDAC1^C; *i.e.*, HDAC1³⁷⁷⁻⁴⁸²) interacts with the MTA1^{BAH} domain (Fig.
222 2B). Although it has been shown that the MTA1-HDAC1 dimer can form in the absence of
223 MTA1^{BAH} (Millard et al., 2013), this additional interaction between MTA1 and HDAC1 could be
224 functionally important. Consistent with this possibility, mutations in HDAC1^C (Δ 391-482, S421A,
225 S423A, E426A) have been known to disrupt binding to NuRD subunits (Pflum et al., 2001).
226 There are also post-translational modifications in the HDAC1 tail that might modulate its
227 interaction with MTA1 (Pflum et al., 2001; Rathert et al., 2008).

228
229 Both the MTA1^{R1}-RBBP4 units are located between the two lobes in the EM map, with one
230 complex in the front and the other at the back (dark blue beads and densities, Fig. 2A-2C). On
231 the other hand, the MTA1^{R2}-RBBP4 complexes are located in separate lobes (light blue beads
232 and densities, Fig. 2A-2C). The densities of RBBP4 are spread out, indicating its localization in
233 MHR is imprecise (Fig. 2B, Movie M1). This is consistent with the structural heterogeneity
234 observed in 2D class averages of the MHR EM data (Low et al., 2020). This flexibility could
235 facilitate RBBP4 interactions with transcription factors and histones.




Fig. 2 Integrative model of the MTA1-HDAC1-RBBP4 (MHR) complex A. Representative bead model from the most populated cluster of integrative models for the MHR complex, shown with the MHR EM map. The model is colored by subunit. For MTA1, the two copies are shown in different colors (brown and orange) in panels A and C, to illustrate the crossover. The HDAC1 active site is shown in red. B. Localization probability density maps showing the position of different domains/subunits in the cluster. The map specifies the probability of any volume element being occupied by a domain in the ensemble of superposed models from the cluster. The domain densities are colored according to Fig S1. These maps are contoured at ~10% of their respective maximum voxel values. C. Schematic representation of the integrative model of the MHR complex. See also Figs. S1, S3, S6, and Movie M1.

MHM

Integrative modeling of the 2:2:2 MHM complex resulted in a major cluster containing 60% of 21960 models. The model precision was 24 Å and 99% of the input crosslinks were satisfied (Fig. S4, Fig. S7). The cross-correlation between the localization probability density map for the models in the major cluster and the input EM map was 0.90.

252

253 First, in a control run, where MHM was modeled as a 2:2:1 complex with a single copy of MBD3,
254 we observed two symmetric MBD3 binding sites (Fig. S10). However, our 2:2:2 MHM model
255 shows that the two copies of MBD3 bind asymmetrically on the MTA1-HDAC1 dimer (Fig. 3A-
256 3C, Movie M2). One MBD3 localizes exclusively to one end of the MTA1-HDAC1 dimer, making
257 contacts predominantly with a single MTA1 and HDAC1 (pink MBD3, Fig. 3C), whereas the
258 other MBD3 is more spread out and interacts with both copies of MTA1 and HDAC1 (green
259 MBD3, Fig. 3C).

260

261 In our models, both the copies of MBD3^{MBD} localize close to the MTA1^{BAH} domain, which is
262 similar to the location observed for MBD2^{MBD} in an independent cryo-EM map of a 2:2:1
263 MTA1:HDAC1:MBD2 complex (Fig. 3A-3C) (Millard et al., 2020). Although there are two
264 MBD3s in our models, only a single MBD3^{IDR} localizes to the MTA1 dimerization interface,
265 MTA1^{dimer} (green MBD3, Fig. 3D-3E). This localization of MBD3^{IDR} is consistent with its
266 previously predicted localization from the crosslinks-based model (Low et al., 2020) and the
267 localization of MBD2^{IDR} based on cryo-electron microscopy (Millard et al., 2020). It is also
268 supported by two separate mutagenesis and co-immunoprecipitation studies, one of which
269 showed that MBD2^{IDR} was essential for binding to the MTA1-HDAC1 dimer (Desai et al., 2015),
270 while the other showed that MTA1^{dimer} was essential for its interaction with MBD2 (Millard et al.,
271 2020). It is known that MBD3 binding in NuDe/NuRD is asymmetric; although there are two
272 symmetric MBD3 binding sites, there is a single MBD3 in these complexes (Low et al., 2020).
273 It is possible that a single MBD3 is present in NuDe/NuRD since a single MBD3^{IDR} can bind to
274 the MTA1^{dimer} (see also Discussion).

275

276 For both MBDs, the MBD3^{MBD} domain is proximal to the MTA1^{BAH} domain and the MBD3^{IDR} is
277 close to the MTA1^{mid} region (Fig. 3B, Fig. 3E). The MBD3^{CC}-GATAD2^{CC} coiled-coil domain is
278 exposed. Finally, in a small minority of models, both MBDs are localized together on the same
279 side of the MTA1^{dimer}; however, we believe this latter configuration is possibly due to a large
280 number of intra-MBD3 crosslinks (Movie M2).




Fig. 3 Integrative model of the MTA1^N-HDAC1-MBD3^{GATAD2CC} (MHM) complex A. Representative bead model from the major cluster of analyzed integrative models for the MHM complex, with the corresponding EM map (EMD-21382) (Low et al., 2020), colored by subunit. The domains of the two MBD3s are shown in shades of pink and green respectively. B. Localization probability density maps showing the position of different domains in the ensemble of models from the cluster. The domain densities are colored according to Fig S1. C. The same density maps as B (front view), showing the two MBDs in pink and green respectively, illustrating that they localize differently on the MTA1-HDAC1 dimer. The density maps of MTA1^{mid} and GATAD2^{CC} were omitted for clarity. D. The density maps of the two MBD3^{IDR} domains on the MTA1-HDAC1 dimer. Almost all the maps are contoured at 20% of their respective maximum voxel values (GATAD2 maps are contoured at 27% whereas MBD3^{IDR} maps are contoured at 10%). E. Schematic representation of the integrative model of the MHM complex. Note that MTA1^{mid} in this model corresponds to MTA1³³⁴⁻⁴³¹. See also Figs. S1, S4, S7, and Movie M2.

281
282
283
284
285
286
287
288
289
290
291
292
293

294 NuDe

295 Although the NuDe complex contains full-length GATAD2, due to the lack of information on full-
296 length GATAD2, we modeled only the GATAD2 region that forms a coiled-coil with MBD3.
297 Integrative modeling of the NuDe complex resulted in effectively a single cluster (99% of 21632
298 models). The model precision was 35 Å and 99% of the input crosslinks were satisfied (Fig. S5,
299 Fig. S8). The cross-correlation between the localization probability density map for the models
300 in the major cluster and the input EM map was 0.88.

301
302 In contrast to our MHM model where one MBD3 was proximal to the MTA1^{SANT} domain, MBD3
303 in NuDe localizes precisely to one end of the MTA1-HDAC1 dimer, away from the MTA1^{SANT}
304 domain. It is juxtaposed next to the MTA1^{BAH} and MTA1^{mid} domains, as well as HDAC1 (Fig.
305 4A-4C, Movie M3). An independent cryo-EM map of MTA1¹⁻⁵⁴⁶-HDAC1-MBD2-RBBP4 also
306 showed that MBD3 was proximal to MTA1^{BAH} and MTA1^{dimer} (Millard et al., 2020). It is possible
307 that the presence of GATAD2 sterically precludes MBD3 from occupying the MTA1 dimerization
308 interface (see also Discussion).

309
310 From protein-protein distance maps of the cluster, HDAC1⁶⁰⁻¹⁰⁰ and MTA1^{BAH} are most proximal
311 to MBD3 (Fig. S11A, S11B). MBD3^{CC}-GATAD2^{CC} is exposed. The MBD3^{MBD} domain is buried,
312 consistent with the failure of MBD3 to bind DNA in NuRD noted in immuno-precipitation
313 experiments (Fig. 4A-4C) (Zhang et al., 1999). Interestingly, several nucleosome-interacting
314 domains such as MTA1^{BAH} and MTA1^{ZF} are co-localized in the NuDe model (Fig. 4A-4C).

315
316 Similar to the MHR models, the HDAC1^C domain is proximal to MTA1^{BAH} (Fig. S11C).
317 Mutagenesis and co-immunoprecipitation studies have shown that HDAC1^C makes critical
318 interactions with NuRD subunits (Pflum et al., 2001). In contrast to the MHR models which
319 showed crossover of MTAs, the two MTAs are well-separated in NuDe (Fig. 4A-4C). The
320 localization of RBBPs is also more precise in NuDe than in MHR (Fig. S12).





Fig. 4 Integrative model of the nucleosome deacetylase (NuDe) complex A. Representative bead model from the dominant cluster of integrative models for the NuDe complex, with the corresponding EM map (EMD-22904) (Low et al., 2020), colored by subunit. B. Localization probability density maps showing the position of different domains in the ensemble of models from the cluster. The domain densities are colored according to Fig S1. Maps are contoured at ~10% of their respective maximum voxel values. C. Schematic representation of the integrative model of the NuDe complex. See also Figs. S1, S5, S8, S11, and Movie M3.

Mapping COSMIC mutations

We next consulted the COSMIC (Catalogue of Somatic Mutations in Cancer) database for somatic, confirmed pathogenic, point mutations of the NuRD subunits, MTA1, HDAC1, RBBP4, and MBD3 (Forbes et al., 2006). In total, 356 point mutations were identified and mapped onto the cluster of NuDe integrative models (Methods, 4.5 COSMIC data analysis). Analysis of these mutations revealed that 74% of mutations mapped to protein-protein interfaces within NuDe; for the purpose of this analysis, a mutation was considered to be at an interface if the average distance of the corresponding residue to a residue in an interacting protein is less than 10 Å. 29% of the mapped mutations were located in previously uncharacterized binding interfaces predicted by our model, such as MBD3-MTA1^{BAH}, MBD3-HDAC1⁶⁰⁻¹⁰⁰, and HDAC1^C-MTA1^{BAH}, consistent with the idea that these interfaces are important for NuRD function (Fig. 5, Fig. S13,

341 Table S1). Mutations at protein-protein interfaces could alter protein-protein interactions,
 342 reducing the stability of the complex, thereby leading to pathogenicity. Moreover, 19% of all
 343 mutations mapped to exposed regions that are known to bind to nucleosomes and transcription
 344 factors, such as the HDAC1 active site and RBBP4 H3 interaction site (Fig. 5, Fig. S13, Table
 345 S1). These mutations could impair NuRD binding to partners such as nucleosomes or
 346 transcription factors, contributing to the pathogenesis of disease. Of the 19% that map to
 347 exposed regions, more than half (57%) of the mutations map to regions of unknown structure
 348 (regions for which no experimental structure or reliable model is available), such as MTA1^{USR}
 349 and MBD3^{IDR} (Fig. 5, Table S1). The functional significance of these mutations is therefore
 350 difficult to predict, but could indicate that these regions of unknown structure also have
 351 important roles in protein stability, regulating interactions between NuRD subunits, or
 352 interactions with binding partners of NuRD. An important consideration for all these disease-
 353 causing mutations is that many of the NuRD subunits function in cellular contexts independent
 354 of other NuRD subunits, and so in some cases these mutations may be rationalised in the
 355 context of other functional roles.



356
 357 **Fig. 5 COSMIC mutations mapped onto the NuDe integrative model.** Somatic pathogenic point mutations from
 358 the COSMIC database (Forbes et al., 2006) mapped onto the representative bead model of the NuDe complex
 359 (Fig. 4A). A. Mutations of residues that map to previously undescribed protein-protein interfaces within our model.
 360 Residues from two proteins are at an interface if the average distance between their corresponding bead surfaces
 361 is less than 10 Å in the cluster of NuDe integrative models. B. Mutations on residues that map to exposed binding
 362 sites between modeled proteins and known binding partners. A bead is colored according to the maximum number
 363 of mutations on any residue in the bead, according to the legend. Representative mutations are labeled in both A.
 364 and B. See also Table S1 and Fig. S13.

365 366 **Docking the nucleosome**

367 We next attempted to dock the CHD4-nucleosome structure (Farnung et al., 2020) into the cleft
 368 in the NuDe structure between the MTA1 C-terminal arms (Fig. 6). Although there are limitations
 369 to this docking (for example, it is a coarse placement, lacks histone tail densities, and binding
 370 sites for the nucleosome outside the cleft might also exist), this positioning of the nucleosome

371 indicates its size complementarity to the integrative model, further corroborating the latter. This
372 placement allows for the histone H3 and H4 tails to be located towards the HDAC1 active site.
373 It also accommodates the known interactions between the RBPs and the histone H3 (Fig. 6).
374 The partial CHD4 structure is exposed. MTA1^{mid}, which contains the zinc finger, can also
375 potentially interact with the nucleosome in this position. Finally, MBD3 does not interact with
376 the nucleosome, since MBD3^{MBD} is buried in NuDe (Fig. 4A-4C), consistent with MBD3 in NuRD
377 failing to bind DNA in immuno-precipitation experiments (Zhang et al., 1999).
378




Fig. 6 Integrative model of NuDe complex with the nucleosome The CHD4- nucleosome structure (Farnung et al., 2020) is placed in the cleft of the NuDe integrative model. The regions with known atomic structure are shown in the NuDe integrative model from Fig. 4A. Nucleosome proteins/DNA and the corresponding NuDe subunit residues they are known to bind to, are depicted in the same color, as given by the legend.

385 Discussion

386 Here, we obtained structural models of the MTA1-HDAC1-RBBP4 (MHR), MTA1^N-HDAC1-
387 MBD3 (MHM), and MTA1-HDAC1-RBBP4-MBD3-GATAD2 (NuDe) complexes using Bayesian
388 integrative modeling. The approach allowed us to combine all available structural information,
389 including data from SEC-MALLS, DIA-MS, chemical crosslinking mass spectrometry (XLMS),
390 negative stain EM, X-ray crystallography, NMR spectroscopy, secondary structure, and
391 homology predictions (Methods, Fig. 1) (Alqarni et al., 2014; Connelly et al., 2006; Cramer et
392 al., 2014; Gnanapragasam et al., 2011; Low et al., 2020; Millard et al., 2016, 2013; Söding et
393 al., 2005; Tjandra et al., 1997). The models were corroborated by independent cryo-EM maps,
394 enzyme assays, mutagenesis, co-immunoprecipitation studies, and the mapping of cancer
395 mutations (Fig. 5, Fig. S13, Table S1) (Desai et al., 2015; Forbes et al., 2006; Millard et al.,
396 2020; Pflum et al., 2001; Zhang et al., 1999). Importantly, our approach allowed us to localize
397 regions of unknown structure, for e.g., HDAC1^C and MBD3^{IDR}, in context of regions of known
398 structure, for e.g., the MTA1-HDAC1 dimer, resulting in the most complete structural
399 characterization of these NuRD sub-complexes so far.


401 NuDe complex is more ordered than MHR

402 A comparison of MTA1 and RBBP4 in the MHR and NuDe models suggests that these subunits
403 are more conformationally heterogeneous in MHR, as shown by the broader localization
404 probability densities for the C-terminal half of MTA1 and RBPs in MHR (volume enclosed by
405 the corresponding maps = 1120 nm³) compared to NuDe (volume enclosed = 883.6 nm³) (Fig.

406 S12). Also, the cross-correlation of the MHR localization probability density to the
 407 corresponding EM map is lower than that of NuDe, indicating higher heterogeneity for the
 408 former. This indicates that the MHR is initially dynamic and the presence of MBD3-GATAD2
 409 possibly makes it less dynamic.
 410

411 **MBD3^{IDR} – MTA1^{dimer} interaction**

412 In our MHM models, one MBD3^{IDR} is near the MTA1^{dimer}, consistent with the previously
 413 predicted localization of MBD3^{IDR} based on chemical crosslinks (Low et al., 2020) and MBD2^{IDR}
 414 based on a cryo-electron density map (Fig. 3C-3E) (Millard et al., 2020). Two separate
 415 mutagenesis and co-immunoprecipitation studies have shown that the MBD^{IDR} and the MTA1
 416 dimerization interface are each essential for MBD2 interaction with the MTA1-HDAC1 dimer
 417 (Desai et al., 2015; Millard et al., 2020). Despite the corresponding region of MBD2 being
 418 disordered in solution (Desai et al., 2015), MBD3¹²⁵⁻¹⁷⁵ is predicted to be ordered based on
 419 PONDR[®] analysis (Fig. S14) (<http://www.pondr.com>) (Romero et al., 2001, 1997). Because this
 420 region is well conserved across species (Cramer et al., 2017), it is likely that it becomes ordered
 421 upon binding, similar to the region of MTA1 that winds irregularly across the surface of HDAC1
 422 (MTA1¹⁶⁵⁻²²⁶). Further, the crosslinks between MBD3^{IDR} and MTA1 involve a loop (MTA1²²⁹⁻²³⁶)
 423 of the MTA1^{dimer} that is not visible in the MTA1-HDAC1 crystal structure. It is possible that this
 424 region of MTA1 may also become ordered upon binding MBD3.



425 **Fig. 7 Bind-and-shift model of MBD3 binding to MHR** The figure shows two stages of MBD3 assembly in NuRD.
 426 A. In the first stage, the MTA1 dimerization interface is accessible for MBD3^{IDR} to bind. B. In the second stage,
 427 upon binding, MBD3 recruits GATAD2 and the chromatin remodeling module and shifts to one end of the MTA1-
 428 HDAC1 dimer. GATAD2 localizes near MTA1dimer, precluding a second MBD3 from binding to it.
 429
 430

431

432 **Bind-and-shift model of MBD3 binding to MHR**

433 The stoichiometry of MBD3 in NuRD is intriguing. The MHM complex has two copies of MBD3,
434 while a single MBD3 is seen in the NuDe and NuRD complexes (Low et al., 2020). Based on
435 our integrative models, we propose a two-stage mechanism to explain the asymmetric binding
436 of MBD3 in NuRD (Fig. 7).

437

438 In the first stage (Fig. 7A), the C-terminal arms of MTA1 in MHR are heterogenous and adopt
439 a range of configurations including an extended, open state (Millard et al., 2020) and crossed-
440 over state (Fig. 2, MHR models). In the open state, the MTA1 dimerization interface is
441 accessible for MBD3^{IDR} to bind. This interaction of MBD3^{IDR} with the MTA1^{dimer} is also observed
442 in a cryo-EM study on MTA1:HDAC1:MBD2 and is known to be critical for MBD recruitment to
443 the deacetylase module (Fig. 3, MHM models) (Desai et al., 2015; Millard et al., 2020).

444

445 In the second stage (Fig. 7B), upon binding to MTA1^{dimer}, MBD3 recruits GATAD2 and the
446 chromatin remodeling module and shifts to one end of the MTA1-HDAC1 dimer (Fig. 4, NuDe
447 models). In this state, GATAD2 localizes near MTA1^{dimer}, precluding a second MBD3 from
448 binding to it. Although we did not model full GATAD2 in NuDe due to unavailability of structures
449 and crosslinks involving the protein, the proximity of CHD4, and hence GATAD2, to the
450 MTA1^{dimer} in our coarse nucleosome docking supports this idea (Fig. 6). This possibly explains
451 how GATAD2 introduces asymmetry of MBD3 binding in NuRD. Moreover, upon binding
452 the chromatin remodeling module, the C-terminal arms of MTA1 with the RBPs are less
453 heterogenous and adopt a closed configuration (Fig. 4, Fig. S12).

454

455 The novel NuRD protein interfaces predicted by our model need to be confirmed by future
456 experiments. High-resolution structures of regions such as MBD3^{IDR} will delineate their roles in
457 NuRD. Ultimately, a complete atomic characterization of the NuRD complex will aid in
458 understanding NuRD-mediated regulation of gene expression.

459

460 **Materials and Methods**

461 **Integrative modeling**

462 The integrative structure determination of the NuRD sub-complexes proceeded through four
463 stages (Fig. 1) (Alber et al., 2007; Rout and Sali, 2019; Russel et al., 2012). The modeling
464 protocol (i.e., stages 2, 3, and 4) was scripted using the Python Modeling Interface (PMI)
465 package, a library for modeling macromolecular complexes based on open-source Integrative
466 Modeling Platform (IMP) package, version 2.13.0 (<https://integrativemodeling.org>) (Russel et
467 al., 2012). The current procedure is an updated version of previously described protocols
468 (Ganesan et al., 2020; Gutierrez et al., 2020; Kim et al., 2018; Saltzberg et al., 2019, 2021;
469 Viswanath et al., 2017a; Webb et al., 2018).

470

471 **Stage 1: Gathering data**

472 The stoichiometry and isoforms of subunits was based on DIA-MS and SEC-MALLS
473 experiments (Fig. S1) (Low et al., 2020). Known atomic structures were used for the MTA1-
474 HDAC1 dimer, MTA1^{R1} and MTA1^{R2} domains in complex with RBBP4, and MBD domain of
475 MBD3 (Fig. S1) (Alqarni et al., 2014; Cramer et al., 2014; Millard et al., 2016, 2013). The
476 MTA1^{BAH} domain, MTA1^H, MTA1^{ZF}, and MBD3^{CC}-GATAD2A^{CC} structures were homology-

477 modeled based on the structures of related templates (Fig. S1A) (Connelly et al., 2006;
478 Gnanapragasam et al., 2011; Tjandra et al., 1997).

479
480 The shapes of the complexes were based on 3D negative-stain EM maps; MHR: to be
481 deposited (24.56 Å), MHM: EMD-21382 (20 Å), and NuDe: EMD-22904 (20 Å) (Low et al.,
482 2020). The negative-stained EM map for the MHR complex was produced by further analysis
483 of data reported in a previous study (Fig. S2) (Low et al., 2020). 25,155 particle images were
484 subjected to multiple rounds of 2D classification in CryoSparc (Punjani et al., 2017), following
485 which an *ab initio* 3D reconstruction was obtained and refined by homogenous 3D refinement.
486 The final map was produced from 13,299 particles and had an estimated resolution of ~25 Å
487 according to the FSC0.143 criterion.

488
489 Chemical crosslinks informed the relative localization of the NuRD subunits. A total of 936
490 crosslinks, including 877 BS3DSS (bis(sulfosuccinimidyl)suberate - disuccinimidyl suberate),
491 40 DMTMM (dimethoxy triazinyl methyl-morpholinium chloride), and 19 ADH (adipic acid
492 dihydrazide) crosslinks were used (Low et al., 2020). The models were validated by
493 independent EM maps (Millard et al., 2020), biochemical assays (Desai et al., 2015; Pflum et
494 al., 2001; Zhang et al., 1999), and human cancer-associated mutations on NuRD proteins
495 (Forbes et al., 2006).

496

497 **Stage 2: Representing the system and translating data into spatial restraints**

498 The stoichiometry and representation of subunits is shown (Fig. S1). The domains with known
499 atomic structures were represented in a multi-scale manner with 1 and 10 residues per bead to
500 maximize computational efficiency. These domains were modeled as rigid bodies where the
501 relative distances between beads is constrained during sampling. In contrast, domains without
502 known structure were coarse-grained at 30 residues per bead and modeled as flexible strings
503 of beads.

504

505 We next encoded the spatial restraints into a scoring function based on the information
506 gathered in Stage 1, as follows:

507 (1) *Cross-link restraints*: The Bayesian cross-links restraint (Rieping et al., 2005) was used to
508 restrain the distances spanned by the cross-linked residues (Shi et al., 2014).

509 (2) *EM restraints*: The Bayesian EM density restraint was used to restrain the shape of the
510 modeled complexes and was based on the cross-correlation between the Gaussian Mixture
511 Model (GMM) representations of the NuRD subunits and the GMM representation of the
512 corresponding negative-stain EM density maps (Bonomi et al., 2019).

513 (3) *Excluded volume restraints*: The excluded volume restraints were applied to each bead,
514 using the statistical relationship between the volume and the number of residues that it covered
515 (Alber et al., 2007).

516 (4) *Sequence connectivity restraints*: We applied the sequence connectivity restraints, using a
517 harmonic upper distance bound on the distance between consecutive beads in a subunit, with
518 a threshold distance equal to twice the sum of the radii of the two connected beads. The bead
519 radius was calculated from the excluded volume of the corresponding bead, assuming standard
520 protein density (Shi et al., 2014).

521

522 **Stage 3: Structural sampling to produce an ensemble of structures that satisfies the**
523 **restraints**

524 We aimed to maximize the precision at which the sampling of good-scoring solutions was
525 exhaustive (Stage 4). The sampling runs relied on Gibbs sampling, based on the Replica
526 Exchange Monte Carlo algorithm (Saltzberg et al., 2019, 2021). The positions of the rigid bodies
527 (domains with known structure) and flexible beads (domains with unknown structure) were
528 sampled.

529

530 The initial positions of the flexible beads and rigid bodies in all complexes were randomized,
531 with one exception. For MHR, we were able to unambiguously dock the structure of the MTA1-
532 HDAC1 core in the EM map, with the help of the previous EM map (EMD-3399) (Millard et al.,
533 2016). Hence the position of the corresponding rigid body was fixed throughout.

534

535 The Monte Carlo moves included random translations of individual beads in the flexible
536 segments and rigid bodies (around 3.7 Å and 1.3 Å respectively). A model was saved every 10
537 Gibbs sampling steps, each consisting of a cycle of Monte Carlo steps that moved every bead
538 and rigid body once.

539

540 The sampling produced a total of 40 million MHR, 48 million MHM, and 80 million NuDe
541 integrative models.

542

543 **Stage 4: Analysing and validating the ensemble of structures and data**

544 The sampled models were analysed to assess sampling exhaustiveness and estimate the
545 precision of the structure, its consistency with input data and consistency with data not used in
546 modeling. The structure was further validated by experiments based on the predictions from
547 the models. We used the analysis and validation protocol published earlier (Rout and Sali,
548 2019; Saltzberg et al., 2019, 2021; Viswanath et al., 2017b). Assessment began with a test of
549 the thoroughness of structural sampling, including structural clustering of the models,
550 estimating model precision, and visualizing the variability in the ensemble of structures using
551 localization probability density maps (Viswanath et al., 2017b). The precision of a domain refers
552 to its positional variation in an ensemble of superposed models. It can also be visualized by the
553 localization probability density map for the domain. A localization probability density map
554 specifies the probability of a voxel (3D volume unit) being occupied by a bead in a set of
555 superposed models. The models and densities were visualized with UCSF Chimera and
556 ChimeraX (Pettersen et al., 2021, 2004).

557

558 (1) *Determining good-scoring models*

559 Starting from the millions of sampled models, first, we selected models obtained after score
560 equilibration and clustered them based on the restraint scores (Saltzberg et al., 2021). For
561 further analysis, we considered 15200 MHR, 21960 MHM, and 21632 NuDe good-scoring
562 models that satisfy the data restraints sufficiently well.

563

564 (2) *Clustering and structure precision*

565 We next assessed the sampling exhaustiveness and performed structural clustering (Saltzberg
566 et al., 2019, 2021; Viswanath et al., 2017b). Integrative structure determination resulted in
567 effectively a single cluster for all complexes, at a precision of 26.8 Å (MHR), 23.8 Å (MHM), and
568 34.6 Å (NuDe). The cluster precision is the bead RMSD from the cluster centroid model
569 averaged over all models in the cluster (Viswanath et al., 2017b).

570

571 (3) *Fit to input information*

572 The dominant clusters from each modeled NuRD sub-complex satisfied over 95% of all the
573 BS3DSS, ADH, and DMTMM crosslinks used; a crosslink is satisfied by a cluster of models if
574 the corresponding C α -C α distance in any model in the cluster is less than 35Å, 35Å, 25Å for
575 BS3DSS, ADH, and DMTMM crosslinks respectively. The agreement between the models and
576 the corresponding EM maps was computed by calculating the cross-correlation of the combined
577 localization probability densities of all subunits for the major cluster with the experimental EM
578 map using the *fitmap* tool in UCSF Chimera (Fig. 2-4) (Pettersen et al., 2004). The remainder
579 of the restraints are harmonic, with a specified standard deviation. The cluster generally
580 satisfied the excluded volume and sequence connectivity restraints. A restraint is satisfied by a
581 cluster of models if the restrained distance in any model in the cluster (considering restraint
582 ambiguity) is violated by less than 3 standard deviations, specified for the restraint. Most of the
583 violations are small, and can be rationalized by local structural fluctuations, coarse-grained
584 representation of the model, and/or finite structural sampling.

585

586 (4) *Fit to data not used in modeling*

587 The MHR integrative models were supported by histone deacetylation assays, mutagenesis,
588 and co-immunoprecipitation showing that MTA1 and the HDAC1^C regulate HDAC1 deacetylase
589 activity and NuRD assembly (Pflum et al., 2001; Zhang et al., 1999). The localization of domains
590 such as MTA1^{BAH} and RBBP4 were validated by their consistency with independently
591 determined cryo-EM maps (Millard et al., 2020).

592

593 The MHM integrative models were supported by independent cryo-EM maps of the complex
594 showing similar localizations for MBD2^{MBD} and MTA1^{BAH} (Millard et al., 2020). The MBD3^{IDR}-
595 MTA1^{dimer} interaction was also supported by two separate mutagenesis and co-
596 immunoprecipitation studies (Desai et al., 2015; Millard et al., 2020).

597

598 The NuDe integrative models were corroborated by immunoprecipitation experiments showing
599 that the MBD domain of MBD3 is buried in NuRD (Zhang et al., 1999). They were also
600 supported by independent cryo-EM maps showing that MBD3 is proximal to MTA1^{BAH}, and
601 biochemical assays showing the importance of HDAC1^C interactions in NuRD (Millard et al.,
602 2020; Pflum et al., 2001). The mapping of cancer mutations to protein-protein interfaces in the
603 NuDe model also supported them (Fig. 5, Fig. S13, Table S1) (Forbes et al., 2006).

604

605 4.1 *Mapping COSMIC mutations*

606 We obtained a total of 356 somatic, confirmed pathogenic, point mutations for the modeled
607 NuRD subunits (MTA1, HDAC1, RBBP4, MBD3) from the COSMIC (Catalogue of Somatic
608 Mutations in Cancer) database (Forbes et al., 2006). For each subunit, point mutations were
609 selected from search results based on the presence of census genes and correct
610 documentation of current structures. To ensure the mutations studied significantly affect the
611 function, folding, and protein-protein interaction of the protein, the “confirmed pathogenic” and
612 “somatic” filters were applied in all cases.

613

614

615

616 Acknowledgements

617 We thank Vinothkumar Kutti Ragunath for useful comments on the manuscript.

618

619 Molecular graphics images were produced using the UCSF Chimera and UCSF ChimeraX
620 packages from the Resource for Biocomputing, Visualization, and Informatics at the University
621 of California, San Francisco (supported by NIH P41 RR001081).

622 Funding

623 This work has been supported by the following grants: Department of Atomic Energy (DAE)
624 TIFR grant RTI 4006 and Department of Science and Technology (DST) SERB grant
625 SPG/2020/000475 from the Government of India to S.V, National Health and Medical Research
626 Council of Australia project grants: APP1012161, APP1063301, APP1126357 to M.J.L. and
627 J.P.M. and a fellowship (APP1058916) from the same organization to J.P.M.

628

629 Conflict of Interest

630 None declared.

631

632 References

- 633 Alber, F., Dokudovskaya, S., Veenhoff, L.M., Zhang, W., Kipper, J., Devos, D., Suprpto, A.,
634 Karni-Schmidt, O., Williams, R., Chait, B.T., Rout, M.P., Sali, A., 2007. Determining the
635 architectures of macromolecular assemblies. *Nature* 450, 683–694.
636 <https://doi.org/10.1038/nature06404>
- 637 Alqarni, S.S.M., Murthy, A., Zhang, W., Przewloka, M.R., Silva, A.P.G., Watson, A.A., Lejon,
638 S., Pei, X.Y., Smits, A.H., Kloet, S.L., Wang, H., Shepherd, N.E., Stokes, P.H., Blobel,
639 G.A., Vermeulen, M., Glover, D.M., Mackay, J.P., Laue, E.D., 2014. Insight into the
640 Architecture of the NuRD Complex. *J. Biol. Chem.* 289, 21844–21855.
641 <https://doi.org/10.1074/jbc.M114.558940>
- 642 Basta, J., Rauchman, M., 2017. Chapter 3 - The Nucleosome Remodeling and Deacetylase
643 Complex in Development and Disease, in: Laurence, J., Beusekom, M.V. (Eds.),
644 Translating Epigenetics to the Clinic. Academic Press, Boston, pp. 37–72.
645 <https://doi.org/10.1016/B978-0-12-800802-7.00003-4>
- 646 Basta, J., Rauchman, M., 2015. The nucleosome remodeling and deacetylase complex in
647 development and disease. *Transl. Res. J. Lab. Clin. Med.* 165, 36–47.
648 <https://doi.org/10.1016/j.trsl.2014.05.003>
- 649 Bode, D., Yu, L., Tate, P., Pardo, M., Choudhary, J., 2016. Characterization of Two Distinct
650 Nucleosome Remodeling and Deacetylase (NuRD) Complex Assemblies in Embryonic
651 Stem Cells*. *Mol. Cell. Proteomics* 15, 878–891.
652 <https://doi.org/10.1074/mcp.M115.053207>
- 653 Bonomi, M., Hanot, S., Greenberg, C.H., Sali, A., Nilges, M., Vendruscolo, M., Pellarin, R.,
654 2019. Bayesian Weighing of Electron Cryo-Microscopy Data for Integrative Structural
655 Modeling. *Structure* 27, 175-188.e6. <https://doi.org/10.1016/j.str.2018.09.011>
- 656 Bornelöv, S., Reynolds, N., Xenophontos, M., Gharbi, S., Johnstone, E., Floyd, R., Ralser, M.,
657 Signolet, J., Loos, R., Dietmann, S., Bertone, P., Hendrich, B., 2018. The Nucleosome
658 Remodeling and Deacetylation Complex Modulates Chromatin Structure at Sites of

- 659 Active Transcription to Fine-Tune Gene Expression. *Mol. Cell* 71, 56-72.e4.
660 <https://doi.org/10.1016/j.molcel.2018.06.003>
- 661 Burgold, T., Barber, M., Kloet, S., Cramard, J., Gharbi, S., Floyd, R., Kinoshita, M., Ralser, M.,
662 Vermeulen, M., Reynolds, N., Dietmann, S., Hendrich, B., 2019. The Nucleosome
663 Remodelling and Deacetylation complex suppresses transcriptional noise during lineage
664 commitment. *EMBO J.* 38, e100788. <https://doi.org/10.15252/embj.2018100788>
- 665 Connelly, J.J., Yuan, P., Hsu, H.-C., Li, Z., Xu, R.-M., Sternglanz, R., 2006. Structure and
666 Function of the *Saccharomyces cerevisiae* Sir3 BAH Domain. *Mol. Cell. Biol.* 26, 3256–
667 3265. <https://doi.org/10.1128/MCB.26.8.3256-3265.2006>
- 668 Cramer, J.M., Pohlmann, D., Gomez, F., Mark, L., Kornegay, B., Hall, C., Siraliev-Perez, E.,
669 Walavalkar, N.M., Sperlazza, M.J., Bilinovich, S., Prokop, J.W., Hill, A.L., Williams, D.C.,
670 2017. Methylation specific targeting of a chromatin remodeling complex from sponges
671 to humans. *Sci. Rep.* 7, 40674. <https://doi.org/10.1038/srep40674>
- 672 Cramer, J.M., Scarsdale, J.N., Walavalkar, N.M., Buchwald, W.A., Ginder, G.D., Williams, D.C.,
673 2014. Probing the Dynamic Distribution of Bound States for Methylcytosine-binding
674 Domains on DNA* *This work was supported, in whole or in part, by National Institutes
675 of Health Grants R01 GM098624 (to D. C. W.) and R01 DK029902 (to G. D. G.). NMR
676 data were acquired using NMR instrumentation in the Virginia Commonwealth University
677 Massey Cancer Center Structural Biology Core, and surface plasmon resonance data
678 were acquired in the Virginia Commonwealth University Massey Cancer Center Flow
679 Cytometry Core, both of which are supported, in part, by NCI Cancer Center Core
680 Support Grant P30 CA016059. *J. Biol. Chem.* 289, 1294–1302.
681 <https://doi.org/10.1074/jbc.M113.512236>
- 682 Denslow, S.A., Wade, P.A., 2007. The human Mi-2/NuRD complex and gene regulation.
683 *Oncogene* 26, 5433–5438. <https://doi.org/10.1038/sj.onc.1210611>
- 684 Desai, M.A., Webb, H.D., Sinanan, L.M., Scarsdale, J.N., Walavalkar, N.M., Ginder, G.D.,
685 Williams, D.C., 2015. An intrinsically disordered region of methyl-CpG binding domain
686 protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex. *Nucleic
687 Acids Res.* 43, 3100–3113. <https://doi.org/10.1093/nar/gkv168>
- 688 Farnung, L., Ochmann, M., Cramer, P., 2020. Nucleosome-CHD4 chromatin remodeler
689 structure maps human disease mutations. *eLife* 9, e56178.
690 <https://doi.org/10.7554/eLife.56178>
- 691 Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague,
692 J., Wooster, R., Futreal, P.A., Stratton, M.R., 2006. Cosmic 2005. *Br. J. Cancer* 94, 318–
693 322. <https://doi.org/10.1038/sj.bjc.6602928>
- 694 Ganesan, S.J., Feyder, M.J., Chemmama, I.E., Fang, F., Rout, M.P., Chait, B.T., Shi, Y.,
695 Munson, M., Sali, A., 2020. Integrative structure and function of the yeast exocyst
696 complex. *Protein Sci. Publ. Protein Soc.* 29, 1486–1501.
697 <https://doi.org/10.1002/pro.3863>
- 698 Gnanapragasam, M.N., Scarsdale, J.N., Amaya, M.L., Webb, H.D., Desai, M.A., Walavalkar,
699 N.M., Wang, S.Z., Zu Zhu, S., Ginder, G.D., Williams, D.C., 2011. p66 α -MBD2 coiled-
700 coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-
701 NuRD complex. *Proc. Natl. Acad. Sci.* 108, 7487–7492.
- 702 Guo, T., Luna, A., Rajapakse, V.N., Koh, C.C., Wu, Z., Liu, W., Sun, Y., Gao, H., Menden, M.P.,
703 Xu, C., Calzone, L., Martignetti, L., Auwerx, C., Buljan, M., Banaei-Esfahani, A., Ori, A.,
704 Iskar, M., Gillet, L., Bi, R., Zhang, J., Zhang, H., Yu, C., Zhong, Q., Varma, S., Schmitt,
705 U., Qiu, P., Zhang, Q., Zhu, Y., Wild, P.J., Garnett, M.J., Bork, P., Beck, M., Liu, K.,
706 Saez-Rodriguez, J., Elloumi, F., Reinhold, W.C., Sander, C., Pommier, Y., Aebersold,

- 707 R., 2019. Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. *iScience*
708 21, 664–680. <https://doi.org/10.1016/j.isci.2019.10.059>
- 709 Gutierrez, C., Chemmama, I.E., Mao, H., Yu, C., Echeverria, I., Block, S.A., Rychnovsky, S.D.,
710 Zheng, N., Sali, A., Huang, L., 2020. Structural dynamics of the human COP9
711 signalosome revealed by cross-linking mass spectrometry and integrative modeling.
712 *Proc. Natl. Acad. Sci.* 117, 4088–4098. <https://doi.org/10.1073/pnas.1915542117>
- 713 Hoffmann, A., Spengler, D., 2019. Chromatin Remodeling Complex NuRD in
714 Neurodevelopment and Neurodevelopmental Disorders. *Front. Genet.* 0.
715 <https://doi.org/10.3389/fgene.2019.00682>
- 716 Hong, W., Nakazawa, M., Chen, Y.-Y., Kori, R., Vakoc, C.R., Rakowski, C., Blobel, G.A., 2005.
717 FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by
718 GATA-1. *EMBO J.* 24, 2367–2378. <https://doi.org/10.1038/sj.emboj.7600703>
- 719 Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool,
720 K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohli, S.A.A., Ballard,
721 A.J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., Back, T., Petersen,
722 S., Reiman, D., Clancy, E., Zielinski, M., Steinegger, M., Pacholska, M., Berghammer,
723 T., Bodenstein, S., Silver, D., Vinyals, O., Senior, A.W., Kavukcuoglu, K., Kohli, P.,
724 Hassabis, D., 2021. Highly accurate protein structure prediction with AlphaFold. *Nature*
725 596, 583–589. <https://doi.org/10.1038/s41586-021-03819-2>
- 726 Kim, S.J., Fernandez-Martinez, J., Nudelman, I., Shi, Y., Zhang, W., Raveh, B., Herricks, T.,
727 Slaughter, B.D., Hogan, J.A., Upla, P., Chemmama, I.E., Pellarin, R., Echeverria, I.,
728 Shivaraju, M., Chaudhury, A.S., Wang, J., Williams, R., Unruh, J.R., Greenberg, C.H.,
729 Jacobs, E.Y., Yu, Z., de la Cruz, M.J., Mironska, R., Stokes, D.L., Aitchison, J.D., Jarrold,
730 M.F., Gerton, J.L., Ludtke, S.J., Akey, C.W., Chait, B.T., Sali, A., Rout, M.P., 2018.
731 Integrative structure and functional anatomy of a nuclear pore complex. *Nature* 555,
732 475–482. <https://doi.org/10.1038/nature26003>
- 733 Kloet, S.L., Baymaz, H.I., Makowski, M., Groenewold, V., Jansen, P.W.T.C., Berendsen, M.,
734 Niazi, H., Kops, G.J., Vermeulen, M., 2015. Towards elucidating the stability, dynamics
735 and architecture of the nucleosome remodeling and deacetylase complex by using
736 quantitative interaction proteomics. *FEBS J.* 282, 1774–1785.
737 <https://doi.org/10.1111/febs.12972>
- 738 Lejon, S., Thong, S.Y., Murthy, A., AlQarni, S., Murzina, N.V., Blobel, G.A., Laue, E.D., Mackay,
739 J.P., 2011. Insights into Association of the NuRD Complex with FOG-1 from the Crystal
740 Structure of an RbAp48·FOG-1 Complex *. *J. Biol. Chem.* 286, 1196–1203.
741 <https://doi.org/10.1074/jbc.M110.195842>
- 742 Li, D.-Q., Kumar, R., 2010. Mi-2/NuRD complex making inroads into DNA-damage response
743 pathway. *Cell Cycle Georget. Tex* 9, 2071–2079. <https://doi.org/10.4161/cc.9.11.11735>
- 744 Low, J.K.K., Silva, A.P.G., Sharifi Tabar, M., Torrado, M., Webb, S.R., Parker, B.L., Sana, M.,
745 Smits, C., Schmidberger, J.W., Brillault, L., Jackman, M.J., Williams, D.C., Blobel, G.A.,
746 Hake, S.B., Shepherd, N.E., Landsberg, M.J., Mackay, J.P., 2020. The Nucleosome
747 Remodeling and Deacetylase Complex Has an Asymmetric, Dynamic, and Modular
748 Architecture. *Cell Rep.* 33, 108450. <https://doi.org/10.1016/j.celrep.2020.108450>
- 749 Millard, C.J., Fairall, L., Ragan, T.J., Savva, C.G., Schwabe, J.W.R., 2020. The topology of
750 chromatin-binding domains in the NuRD deacetylase complex. *Nucleic Acids Res.* 48,
751 12972–12982. <https://doi.org/10.1093/nar/gkaa1121>
- 752 Millard, C.J., Varma, N., Saleh, A., Morris, K., Watson, P., Bottrill, A., Fairall, L., Smith, C.,
753 Schwabe, J., 2016. The structure of the core NuRD repression complex provides insights
754 into its interaction with chromatin. *ELife* 2016. <https://doi.org/10.7554/eLife.13941>

- 755 Millard, C.J., Watson, P.J., Celardo, I., Gordiyenko, Y., Cowley, S.M., Robinson, C.V., Fairall,
756 L., Schwabe, J.W.R., 2013. Class I HDACs Share a Common Mechanism of Regulation
757 by Inositol Phosphates. *Mol. Cell* 51, 57–67.
758 <https://doi.org/10.1016/j.molcel.2013.05.020>
- 759 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C.,
760 Ferrin, T.E., 2004. UCSF Chimera—a visualization system for exploratory research and
761 analysis. *J. Comput. Chem.* 25, 1605–1612. <https://doi.org/10.1002/jcc.20084>
- 762 Pettersen, E.F., Goddard, T.D., Huang, C.C., Meng, E.C., Couch, G.S., Croll, T.I., Morris, J.H.,
763 Ferrin, T.E., 2021. UCSF ChimeraX: Structure visualization for researchers, educators,
764 and developers. *Protein Sci.* 30, 70–82. <https://doi.org/10.1002/pro.3943>
- 765 Pflum, M.K.H., Tong, J.K., Lane, W.S., Schreiber, S.L., 2001. Histone Deacetylase 1
766 Phosphorylation Promotes Enzymatic Activity and Complex Formation*. *J. Biol. Chem.*
767 276, 47733–47741. <https://doi.org/10.1074/jbc.M105590200>
- 768 Punjani, A., Rubinstein, J.L., Fleet, D.J., Brubaker, M.A., 2017. cryoSPARC: algorithms for
769 rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296.
770 <https://doi.org/10.1038/nmeth.4169>
- 771 Rathert, P., Dhayalan, A., Murakami, M., Zhang, X., Tamas, R., Jurkowska, R., Komatsu, Y.,
772 Shinkai, Y., Cheng, X., Jeltsch, A., 2008. Protein lysine methyltransferase G9a acts on
773 non-histone targets. *Nat. Chem. Biol.* 4, 344–346. <https://doi.org/10.1038/nchembio.88>
- 774 Reynolds, N., O’Shaughnessy, A., Hendrich, B., 2013. Transcriptional repressors: multifaceted
775 regulators of gene expression. *Development* 140, 505–512.
776 <https://doi.org/10.1242/dev.083105>
- 777 Rieping, W., Habeck, M., Nilges, M., 2005. Inferential Structure Determination. *Science* 309,
778 303–306. <https://doi.org/10.1126/science.1110428>
- 779 Romero, P., Obradovic, Z., Kissinger, C., Villafranca, J.E., Dunker, A.K., 1997. Identifying
780 disordered regions in proteins from amino acid sequence, in: Proceedings of
781 International Conference on Neural Networks (ICNN’97). Presented at the Proceedings
782 of International Conference on Neural Networks (ICNN’97), pp. 90–95 vol.1.
783 <https://doi.org/10.1109/ICNN.1997.611643>
- 784 Romero, P., Obradovic, Z., Li, X., Garner, E.C., Brown, C.J., Dunker, A.K., 2001. Sequence
785 complexity of disordered protein. *Proteins* 42, 38–48. [https://doi.org/10.1002/1097-0134\(20010101\)42:1<38::aid-prot50>3.0.co;2-3](https://doi.org/10.1002/1097-0134(20010101)42:1<38::aid-prot50>3.0.co;2-3)
- 787 Rout, M.P., Sali, A., 2019. Principles for Integrative Structural Biology Studies. *Cell* 177, 1384–
788 1403. <https://doi.org/10.1016/j.cell.2019.05.016>
- 789 Russel, D., Lasker, K., Webb, B., Velázquez-Muriel, J., Tjioe, E., Schneidman-Duhovny, D.,
790 Peterson, B., Sali, A., 2012. Putting the Pieces Together: Integrative Modeling Platform
791 Software for Structure Determination of Macromolecular Assemblies. *PLoS Biol.* 10,
792 e1001244. <https://doi.org/10.1371/journal.pbio.1001244>
- 793 Saltzberg, D., Greenberg, C.H., Viswanath, S., Chemmama, I., Webb, B., Pellarin, R.,
794 Echeverria, I., Sali, A., 2019. Modeling Biological Complexes Using Integrative Modeling
795 Platform, in: Bonomi, M., Camilloni, C. (Eds.), *Biomolecular Simulations: Methods and
796 Protocols, Methods in Molecular Biology*. Springer, New York, NY, pp. 353–377.
797 https://doi.org/10.1007/978-1-4939-9608-7_15
- 798 Saltzberg, D.J., Viswanath, S., Echeverria, I., Chemmama, I.E., Webb, B., Sali, A., 2021. Using
799 Integrative Modeling Platform to compute, validate, and archive a model of a protein
800 complex structure. *Protein Sci.* 30, 250–261. <https://doi.org/10.1002/pro.3995>
- 801 Schneidman-Duhovny, D., Pellarin, R., Sali, A., 2014. Uncertainty in integrative structural
802 modeling. *Curr. Opin. Struct. Biol.* 28, 96–104. <https://doi.org/10.1016/j.sbi.2014.08.001>

- 803 Sharifi Tabar, M., Mackay, J.P., Low, J.K.K., 2019. The stoichiometry and interactome of the
804 Nucleosome Remodeling and Deacetylase (NuRD) complex are conserved across
805 multiple cell lines. *FEBS J.* 286, 2043–2061. <https://doi.org/10.1111/febs.14800>
- 806 Shi, Y., Fernandez-Martinez, J., Tjioe, E., Pellarin, R., Kim, S.J., Williams, R., Schneidman-
807 Duhovny, D., Sali, A., Rout, M.P., Chait, B.T., 2014. Structural characterization by cross-
808 linking reveals the detailed architecture of a coatomer-related heptameric module from
809 the nuclear pore complex. *Mol. Cell. Proteomics MCP* 13, 2927–2943.
810 <https://doi.org/10.1074/mcp.M114.041673>
- 811 Smeenk, G., Wiegant, W.W., Vrolijk, H., Solari, A.P., Pastink, A., van Attikum, H., 2010. The
812 NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage.
813 *J. Cell Biol.* 190, 741–749. <https://doi.org/10.1083/jcb.201001048>
- 814 Smits, A.H., Jansen, P.W.T.C., Poser, I., Hyman, A.A., Vermeulen, M., 2013. Stoichiometry of
815 chromatin-associated protein complexes revealed by label-free quantitative mass
816 spectrometry-based proteomics. *Nucleic Acids Res.* 41, e28.
817 <https://doi.org/10.1093/nar/gks941>
- 818 Söding, J., Biegert, A., Lupas, A.N., 2005. The HHpred interactive server for protein homology
819 detection and structure prediction. *Nucleic Acids Res.* 33, W244–248.
820 <https://doi.org/10.1093/nar/gki408>
- 821 Spruijt, C.G., Luijsterburg, M.S., Menafrá, R., Lindeboom, R.G.H., Jansen, P.W.T.C.,
822 Edupuganti, R.R., Baltissen, M.P., Wiegant, W.W., Voelker-Albert, M.C., Matarese, F.,
823 Mensinga, A., Poser, I., Vos, H.R., Stunnenberg, H.G., van Attikum, H., Vermeulen, M.,
824 2016. ZMYND8 Co-localizes with NuRD on Target Genes and Regulates Poly(ADP-
825 Ribose)-Dependent Recruitment of GATAD2A/NuRD to Sites of DNA Damage. *Cell Rep.*
826 17, 783–798. <https://doi.org/10.1016/j.celrep.2016.09.037>
- 827 Tjandra, N., Omichinski, J.G., Gronenborn, A.M., Clore, G.M., Bax, A., 1997. Use of dipolar $1H$ -
828 $15N$ and $1H$ - $13C$ couplings in the structure determination of magnetically oriented
829 macromolecules in solution. *Nat. Struct. Biol.* 4, 732–738.
830 <https://doi.org/10.1038/nsb0997-732>
- 831 Toh, Y., Nicolson, G.L., 2009. The role of the MTA family and their encoded proteins in human
832 cancers: molecular functions and clinical implications. *Clin. Exp. Metastasis* 26, 215–
833 227. <https://doi.org/10.1007/s10585-008-9233-8>
- 834 Viswanath, S., Bonomi, M., Kim, S.J., Klenchin, V.A., Taylor, K.C., Yabut, K.C., Umbreit, N.T.,
835 Van Epps, H.A., Meehl, J., Jones, M.H., Russel, D., Velazquez-Muriel, J.A., Winey, M.,
836 Rayment, I., Davis, T.N., Sali, A., Muller, E.G., 2017a. The molecular architecture of the
837 yeast spindle pole body core determined by Bayesian integrative modeling. *Mol. Biol.*
838 *Cell* 28, 3298–3314. <https://doi.org/10.1091/mbc.E17-06-0397>
- 839 Viswanath, S., Chemmama, I.E., Cimermanovic, P., Sali, A., 2017b. Assessing Exhaustiveness
840 of Stochastic Sampling for Integrative Modeling of Macromolecular Structures. *Biophys.*
841 *J.* 113, 2344–2353. <https://doi.org/10.1016/j.bpj.2017.10.005>
- 842 Ward, A.B., Sali, A., Wilson, I.A., 2013. Integrative Structural Biology. *Science* 339, 913–915.
843 <https://doi.org/10.1126/science.1228565>
- 844 Webb, B., Viswanath, S., Bonomi, M., Pellarin, R., Greenberg, C.H., Saltzberg, D., Sali, A.,
845 2018. Integrative structure modeling with the Integrative Modeling Platform. *Protein Sci.*
846 27, 245–258. <https://doi.org/10.1002/pro.3311>
- 847 Yoshida, T., Hazan, I., Zhang, J., Ng, S.Y., Naito, T., Snippert, H.J., Heller, E.J., Qi, X., Lawton,
848 L.N., Williams, C.J., Georgopoulos, K., 2008. The role of the chromatin remodeler Mi-2 β
849 in hematopoietic stem cell self-renewal and multilineage differentiation. *Genes Dev.* 22,
850 1174–1189. <https://doi.org/10.1101/gad.1642808>

- 851 Zhang, W., Aubert, A., Gomez de Segura, J.M., Karuppasamy, M., Basu, S., Murthy, A.S.,
852 Diamante, A., Drury, T.A., Balmer, J., Cramard, J., Watson, A.A., Lando, D., Lee, S.F.,
853 Palayret, M., Kloet, S.L., Smits, A.H., Deery, M.J., Vermeulen, M., Hendrich, B.,
854 Klenerman, D., Schaffitzel, C., Berger, I., Laue, E.D., 2016. The Nucleosome
855 Remodeling and Deacetylase Complex NuRD Is Built from Preformed Catalytically
856 Active Sub-modules. *J. Mol. Biol.* 428, 2931–2942.
857 <https://doi.org/10.1016/j.jmb.2016.04.025>
- 858 Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., Reinberg, D., 1999.
859 Analysis of the NuRD subunits reveals a histone deacetylase core complex and a
860 connection with DNA methylation. *Genes Dev.* 13, 1924–1935.
861

Supplementary Figures and Tables

Molecular architecture of nucleosome remodeling and deacetylase sub-complexes by integrative structure determination

Shreyas Arvindekar¹, Matthew J. Jackman², Jason K.K. Low³, Michael J. Landsberg^{2, *}, Joel P. Mackay^{3, *}, and Shruthi Viswanath^{1, *}

¹National Center for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India

²School of Chemistry and Molecular Biosciences, University of Queensland, QLD, Australia

³School of Life and Environmental Sciences, University of Sydney, NSW, Australia

*Corresponding authors E-mail: m.landsberg@uq.edu.au (M.J.L.); joel.mackay@sydney.edu.au (J.P.M.); shruthiv@ncbs.res.in (S.V.)




Fig. S1 Subunits in NuRD sub-complexes A. Sequences and isoforms of modeled subunits are shown and domains are labeled. Domains are shown in progressively dark shades along the sequence for MTA1, HDAC1, and MBD3. Regions with known structure are represented by rectangles while regions without known structure are represented by beads. PDB IDs are shown for existing subunit structures and templates of homology models. B. Coarse-grained bead representation of subunits and C. stoichiometries of modeled complexes.




Fig. S2 Single particle analysis of the MHR complex. A flowthrough from the micrographs imported into Cryosparc (Punjani et al., 2017) to the final 3D reconstruction of the MHR complex using the ab-initio reconstruction job. 2D classes were generated using 50 classes per run, with particles from non-junk classes used as input to subsequent 2D classification jobs. Non-uniform refinement was not performed on the final structure due to its low resolution.




Fig. S3 Sampling exhaustiveness protocol on MHR models Results of test 1, convergence of the model score, for the 15200 good-scoring models; the scores do not continue to improve as more models are computed essentially independently. The error bar represents the standard deviations of the best scores, estimated by repeating sampling of models 10 times. The red dotted line indicates a lower bound reference on the total score. B. Results of test 2, testing similarity of model score distributions between samples 1 (red) and 2 (blue); the difference in the distribution of scores is significant (Kolmogorov-Smirnov two-sample test p-value less than 0.05) but the magnitude of the difference is small (the Kolmogorov-Smirnov two-sample test statistic D is 0.04); thus, the two score distributions are effectively equal. C. Results of test 3, three criteria for determining the sampling precision (Y-axis), evaluated as a function of the RMSD clustering threshold (X-axis). First, the p-value is computed using the χ^2 -test for homogeneity of proportions (red dots). Second, an effect size for the χ^2 -test is quantified by the Cramer's V value (blue squares). Third, the population of models in sufficiently large clusters (containing at least 10 models from each sample) is shown as green triangles. The vertical dotted grey line indicates the RMSD clustering threshold at which three conditions are satisfied (p-value > 0.05 [dotted red line], Cramer's V < 0.10 [dotted blue line], and the population of clustered models > 0.80 [dotted green line]), thus defining the sampling precision of 41 Å. D. Populations of sample 1 and 2 models in the clusters obtained by threshold-based clustering using the RMSD threshold of 41 Å. Cluster precision is shown for each cluster. E. and F. Results of test 4: comparison of localization probability densities of models from sample A and sample B for the major cluster (84.95% population). The cross-correlation of the density maps of the two samples is greater than 0.96.




Fig. S4 Sampling exhaustiveness protocol on MTA1^N-HDAC1-MBD3^{GATAD2CC} (MHM) models Results of test 1, convergence of the model score, for the 21960 good-scoring models; the scores do not continue to improve as more models are computed essentially independently. The error bar represents the standard deviations of the best scores, estimated by repeating sampling of models 10 times. The red dotted line indicates a lower bound reference on the total score. B. Results of test 2, testing similarity of model score distributions between samples 1 (red) and 2 (blue); the difference in the distribution of scores is significant (Kolmogorov-Smirnov two-sample test p-value less than 0.05) but the magnitude of the difference is small (the Kolmogorov-Smirnov two-sample test statistic D is 0.08); thus, the two score distributions are effectively equal. C. Results of test 3, three criteria for determining the sampling precision (Y-axis), evaluated as a function of the RMSD clustering threshold (X-axis). First, the p-value is computed using the χ^2 -test for homogeneity of proportions (red dots). Second, an effect size for the χ^2 -test is quantified by the Cramer's V value (blue squares). Third, the population of models in sufficiently large clusters (containing at least 10 models from each sample) is shown as green triangles. The vertical dotted grey line indicates the RMSD clustering threshold at which three conditions are satisfied (p-value > 0.05 [dotted red line], Cramer's V < 0.10 [dotted blue line], and the population of clustered models > 0.80 [dotted green line]), thus defining the sampling precision of 28.85 Å. D. Populations of sample 1 and 2 models in the clusters obtained by threshold-based clustering using the RMSD threshold of 28.85 Å. Cluster precision is shown for each cluster. E. and F. Results of test 4: comparison of localization probability densities of models from sample A and sample B for the major cluster (60.23% population). The cross-correlation of the density maps of the two samples is greater than 0.95.




Fig. S5 Sampling exhaustiveness protocol on NuDe integrative models Results of test 1, convergence of the model score, for the 21632 good-scoring models; the scores do not continue to improve as more models are computed essentially independently. The error bar represents the standard deviations of the best scores, estimated by repeating sampling of models 10 times. The red dotted line indicates a lower bound reference on the total score. B. Results of test 2, testing similarity of model score distributions between samples 1 (red) and 2 (blue); the difference in the distribution of scores is significant (Kolmogorov-Smirnov two-sample test p-value less than 0.05) but the magnitude of the difference is small (the Kolmogorov-Smirnov two-sample test statistic D is 0.12); thus, the two score distributions are effectively equal. C. Results of test 3, three criteria for determining the sampling precision (Y-axis), evaluated as a function of the RMSD clustering threshold (X-axis). First, the p-value is computed using the χ^2 -test for homogeneity of proportions (red dots). Second, an effect size for the χ^2 -test is quantified by the Cramer's V value (blue squares). Third, the population of models in sufficiently large clusters (containing at least 10 models from each sample) is shown as green triangles. The vertical dotted grey line indicates the RMSD clustering threshold at which three conditions are satisfied (p-value > 0.05 [dotted red line], Cramer's V < 0.10 [dotted blue line], and the population of clustered models > 0.80 [dotted green line]), thus defining the sampling precision of 45.98 Å. D. Populations of sample 1 and 2 models in the clusters obtained by threshold-based clustering using the RMSD threshold of 45.98 Å. Cluster precision is shown for each cluster. E. and F. Results of test 4: comparison of localization probability densities of models from sample A and sample B for the major cluster (99.96% population). The cross-correlation of the density maps of the two samples is ~0.95.




Fig. S6 Results of crosslinks fit for MHR models CX-CIRCOS (<http://cx-circos.net/>) plots are shown for A. BS3DSS, B. DMTMM, and C. ADH crosslinks on the ensemble of MHR models from the major cluster. Each link depicts a crosslink; its color depicts the minimum distance between the corresponding cross-linked residues in the ensemble, as shown in the color key (top). Histograms showing the distribution of the minimum crosslink distance in the ensemble for D. BS3DSS, E. DMTMM, and F. ADH crosslinks. The red line indicates the distance threshold for a crosslink type.




Fig. S7 Results of crosslinks fit for MTA1^N-HDAC1-MBD3^{GATAD2CC} (MHM) models CX-CIRCOS (<http://cx-circos.net/>) plots are shown for A. BS3DSS, B. DMTMM, and C. ADH crosslinks on the ensemble of MHM models from the major cluster. Each link depicts a crosslink; its color depicts the minimum distance between the corresponding cross-linked residues in the ensemble, as shown in the color key (top). Histograms showing the distribution of the minimum crosslink distance in the ensemble for D. BS3DSS, E. DMTMM, and F. ADH crosslinks. The red line indicates the distance threshold for a crosslink type.




Fig. S8 Results of crosslinks fit for NuDe models CX-CIRCOS (<http://cx-circos.net/>) plots are shown for A. BS3DSS, B. DMTMM, and C. ADH crosslinks on the ensemble of NuDe models from the major cluster. Each link depicts a crosslink; its color depicts the minimum distance between the corresponding cross-linked residues in the ensemble, as shown in the color key (top). Histograms showing the distribution of the minimum crosslink distance in the ensemble for D. BS3DSS, E. DMTMM, and F. ADH crosslinks. The red line indicates the distance threshold for a crosslink type.




Fig. S9 Integrative model of the MHR complex based on crosslinks alone Representative bead model from the most populated cluster of analyzed integrative models for the MHR complex, colored by subunit. The two copies of MTA1 are shown in different colors (orange and brown) to illustrate the crossover.




Fig. S10 Integrative model of the MTA1^N-HDAC1-MBD3^{GATAD2^{CC}} complex with one copy of MBD3 Localization probability density maps showing the position of different domains in the ensemble of models from the major cluster, illustrating two different binding sites for MBD3 on the MTA1-HDAC1 dimer. The density maps were contoured at 30% (HDAC1 structured region), 5% (HDAC1^C, MBD3 and GATAD2^{CC}), 20% (MTA1^{BAH} and MTA1^{ELM2-SANT}), and 10% (MTA1^{MID}) of their respective maximum voxel values.




Fig. S11 Distance maps for protein interactions in NuDe. The distance maps show the average pairwise residue distances in the ensemble of NuDe models for the A. MBD3-MTA1, B. MBD3-HDAC1, and C. HDAC1-MTA1 protein pairs. For a pair of residues, the map indicates the distance between the surfaces of the corresponding beads averaged over the ensemble.




Fig. S12 Densities of RBBPs in MHR and NuDe. The localization probability densities for MTA1^{R1}-RBBP4 and MTA1^{R2}-RBBP4 in MHR (green) and NuDe (blue) are shown. The MHR model shows a broader localization of RBBPs (volume enclosed by the corresponding maps = 1120 nm³), compared to NuDe (volume enclosed = 883.6 nm³). All maps were contoured at 10%.




Fig. S13 COSMIC mutations on the structured regions of NuDe complex Somatic, confirmed pathogenic, point mutations from the COSMIC database (Forbes et al., 2006) mapped onto regions with known structure in the NuDe integrative model shown in Fig. 4A. A. Regions with known atomic structure in the integrative model colored by subunit. B. Mutations on residues in regions of known structure, colored according to the legend.

Intrinsic disorder profile




Fig. S14 Disorder prediction for MBD3 PONDR® (<http://www.pondr.com>) (Romero et al., 2001, 1997) disorder prediction for MBD3.

Table S1. COSMIC Somatic, confirmed pathogenic point mutations from the COSMIC database [(Forbes et al., 2006)] mapped on the NuDe integrative model. A. Mutations in previously undescribed protein-protein interfaces in the model. Residues from two proteins are at an interface if the average distance between their corresponding bead surfaces is less than 10 Å in the cluster of models. B. Mutations in exposed binding sites between modeled proteins and known binding partners, based on the representative NuDe model.

A. COSMIC mutations in previously undescribed protein-protein interfaces in NuDe			
NuRD protein	Residues with mutations	Interacting partner in NuRD	Number of COSMIC mutations
MBD3	68, 78, 80, 85, 87, 98, 103, 107, 138, 148, 150, 236, 260, 271, 275	MTA1 ^{BAH}	1-2
MTA1 ^{BAH}	15, 24, 31, 46, 112, 153, 155, 158	MBD3	1-2
	12	MBD3	5+
MBD3	2, 7, 12, 14, 19, 31, 39, 41, 43, 45, 55, 65, 68, 78, 80, 85, 87, 98, 103, 107, 111, 125, 130, 138, 148, 150, 236, 240, 243, 250, 260, 271, 275	HDAC1 ⁶⁰⁻¹⁰⁰	1-2
	17, 60, 112, 128, 246	HDAC1 ⁶⁰⁻¹⁰⁰	3-4
HDAC1 ⁶⁰⁻¹⁰⁰	61, 64, 69, 73, 80, 86, 94, 96	MBD3	1-2
	62	MBD3	3-4
HDAC1 ^C	411, 420, 423, 425, 431, 435, 447, 462	MTA1 ^{BAH}	1-2
MTA1 ^{BAH}	53, 60, 63, 153, 155, 158	HDAC1 ^C	1-2
B. COSMIC mutations in exposed binding sites to known interactors in NuDe			
NuRD protein	Residues with mutations	Associated partner outside NuRD if known	Number of COSMIC mutations
RBBP4	39, 45, 71, 75, 128, 321, 376, 396, 398	H3, FOG1/2, other ZF containing TFs [(Lejon et al., 2011; Liu et al., 2015; Moody et al., 2018; Schmidberger et al., 2016)]	1-2
RBBP4	40, 378	H3, FOG1/2, other ZF containing TFs [(Lejon et al., 2011; Liu et al., 2015; Moody et al., 2018; Schmidberger et al., 2016)]	3-4
MTA1 ^{BAH}	46, 53, 153, 155, 158	Nucleosome (based on Sir3-BAH PDB 3TU4 [6]), MAT1 [(Millard et al., 2014)]	1-2
MTA1 ^{mid}	390, 393, 394, 397, 401, 410, 416, 420, 424	MAT1 [(Mazumdar et al., 2001)]	1-2
MTA1 ^{mid}	406, 415	MAT1 [(Mazumdar et al., 2001)]	3-4
MTA1 ^{mid}	372	NRIF3 [(Talukder et al., 2004)]	5+
MTA1 ^{USR}	547, 550, 562, 564, 578, 581, 601, 603, 606, 610, 611, 612, 617, 619, 633, 646, 647, 652, 658, 666	MICoA [(Mishra et al., 2003)]	1-2
MTA1 ^{USR}	549, 566, 571	MICoA [(Mishra et al., 2003)]	3-4
MTA1 ^C	697, 699, 705, 709, 715	MICoA [(Mishra et al., 2003)]	1-2
HDAC1 active site	140, 150, 303	Histone tails, TFs [(Scafuri et al., 2020)]	1-2
MBD3 ^{IDR}	77, 78, 80, 85, 87, 97, 98, 102, 103, 107	Evi1 [(Spensberger & Delwel, 2008)], Aurora A [(Sakai et al., 2002)]	1-2

Movies

M1. MHR movie. The movie shows a sample of one thousand models from the ensemble of MHR integrative models.

M2. MHM movie. The movie shows a sample of one thousand models from the ensemble of MHM integrative models.

M3. NuDe movie. The movie shows a sample of one thousand models from the ensemble of NuDe integrative models.

References:

- Armache, K.-J., Garlick, J. D., Canzio, D., Narlikar, G. J., & Kingston, R. E. (2011). Structural Basis of Silencing: Sir3 BAH Domain in Complex with a Nucleosome at 3.0 Å Resolution. *Science*, 334(6058), 977–982. <https://doi.org/10.1126/science.1210915>
- Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A., & Stratton, M. R. (2006). Cosmic 2005. *British Journal of Cancer*, 94(2), 318–322. <https://doi.org/10.1038/sj.bjc.6602928>
- Lejon, S., Thong, S. Y., Murthy, A., AlQarni, S., Murzina, N. V., Blobel, G. A., Laue, E. D., & Mackay, J. P. (2011). Insights into Association of the NuRD Complex with FOG-1 from the Crystal Structure of an RbAp48·FOG-1 Complex *. *Journal of Biological Chemistry*, 286(2), 1196–1203. <https://doi.org/10.1074/jbc.M110.195842>
- Liu, Z., Li, F., Zhang, B., Li, S., Wu, J., & Shi, Y. (2015). Structural Basis of Plant Homeodomain Finger 6 (PHF6) Recognition by the Retinoblastoma Binding Protein 4 (RBBP4) Component of the Nucleosome Remodeling and Deacetylase (NuRD) Complex. *Journal of Biological Chemistry*, 290(10), 6630–6638. <https://doi.org/10.1074/jbc.M114.610196>
- Mazumdar, A., Wang, R.-A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., Vadlamudi, R. K., & Kumar, R. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. *Nature Cell Biology*, 3(1), 30–37. <https://doi.org/10.1038/35050532>
- Millard, C. J., Fairall, L., & Schwabe, J. W. R. (2014). Towards an understanding of the structure and function of MTA1. *Cancer and Metastasis Reviews*, 33(4), 857–867. <https://doi.org/10.1007/s10555-014-9513-5>
- Mishra, S. K., Mazumdar, A., Vadlamudi, R. K., Li, F., Wang, R.-A., Yu, W., Jordan, V. C., Santen, R. J., & Kumar, R. (2003). MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor- α Transactivation Functions*. *Journal of Biological Chemistry*, 278(21), 19209–19219. <https://doi.org/10.1074/jbc.M301968200>

- Moody, R. R., Lo, M.-C., Meagher, J. L., Lin, C.-C., Stevers, N. O., Tinsley, S. L., Jung, I., Matvekas, A., Stuckey, J. A., & Sun, D. (2018). Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. *The Journal of Biological Chemistry*, 293(6), 2125–2136. <https://doi.org/10.1074/jbc.M117.811463>
- Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017). cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. *Nature Methods*, 14(3), 290–296. <https://doi.org/10.1038/nmeth.4169>
- Romero, P., Obradovic, Z., Kissinger, C., Villafranca, J. E., & Dunker, A. K. (1997). Identifying disordered regions in proteins from amino acid sequence. *Proceedings of International Conference on Neural Networks (ICNN'97)*, 1, 90–95 vol.1. <https://doi.org/10.1109/ICNN.1997.611643>
- Romero, P., Obradovic, Z., Li, X., Garner, E. C., Brown, C. J., & Dunker, A. K. (2001). Sequence complexity of disordered protein. *Proteins*, 42(1), 38–48. [https://doi.org/10.1002/1097-0134\(20010101\)42:1<38::aid-prot50>3.0.co;2-3](https://doi.org/10.1002/1097-0134(20010101)42:1<38::aid-prot50>3.0.co;2-3)
- Sakai, H., Urano, T., Ookata, K., Kim, M.-H., Hirai, Y., Saito, M., Nojima, Y., & Ishikawa, F. (2002). MBD3 and HDAC1, Two Components of the NuRD Complex, Are Localized at Aurora-A-positive Centrosomes in M Phase *. *Journal of Biological Chemistry*, 277(50), 48714–48723. <https://doi.org/10.1074/jbc.M208461200>
- Scafuri, B., Bontempo, P., Altucci, L., De Masi, L., & Facchiano, A. (2020). Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding. *Biomedicines*, 8(12). <https://doi.org/10.3390/biomedicines8120568>
- Schmidberger, J. W., Tabar, M. S., Torrado, M., Silva, A. P. G., Landsberg, M. J., Brillault, L., AlQarni, S., Zeng, Y. C., Parker, B. L., Low, J. K. K., & Mackay, J. P. (2016). The MTA1 subunit of the nucleosome remodeling and deacetylase complex can recruit two copies of RBBP4/7. *Protein Science*, 25(8), 1472–1482. <https://doi.org/10.1002/pro.2943>

Spensberger, D., & Delwel, R. (2008). A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. *FEBS Letters*, 582(18), 2761–2767.

<https://doi.org/10.1016/j.febslet.2008.06.056>

Talukder, A. H., Gururaj, A., Mishra, S. K., Vadlamudi, R. K., & Kumar, R. (2004). Metastasis-Associated Protein 1 Interacts with NRIF3, an Estrogen-Inducible Nuclear Receptor Coregulator. *Molecular and Cellular Biology*, 24(15), 6581–6591. <https://doi.org/10.1128/MCB.24.15.6581-6591.2004>